Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma

Please Log In or Register to continue.

Release Date: May 17, 2017
Expiration Date: May 17, 2018

Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Treatment-related adverse events (AEs) can have a significant impact on patients with multiple myeloma, including poorer outcomes, premature discontinuation of therapy, and reduced quality of life. There are a number of characteristic major AEs associated with treatment options for patients with relapsed/refractory disease, which must be monitored for and managed appropriately. In this activity, participants will learn about the major AEs associated with emerging and standard of care agents for relapsed/refractory multiple myeloma (RRMM), including clinical pearls for patient monitoring and toxicity mitigation strategies that can be implemented in clinical practice.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe strategies for managing baseline and treatment-emergent renal and hepatotoxicity for therapies used in relapsed/refractory multiple myeloma
  • Identify therapies associated with infusion reactions in RRMM, and appropriate management strategies for each
  • Recognize the risk of peripheral neuropathy and cardiovascular toxicity associated with specific agents and patient populations

Agenda

Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma – Ajay K. Nooka, MD, MPH, FACP

Instructions for Participation and Credit

This activity is eligible for credit through May 17, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Ajay K. Nooka, MD, MPH, FACP
Assistant Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Dr. Ajay Nooka earned his medical degree from Andhra Medical College in India before relocating to the United States. He received a master’s in public health from The University of Texas School of Public Health in Houston, Texas, and then completed his internship and residency at the Northeastern Ohio University College of Medicine. He also pursued a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. Dr. Nooka is an Assistant Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta.

Dr. Nooka has a clinical interest in myeloma and bone marrow transplant. His research interests mainly involve improving novel therapeutic strategies for plasma cell dyscrasias and improving outcomes of myeloma patients. He has published several peer-reviewed articles in journals such as the New England Journal of Medicine, Lancet Oncology, Leukemia, Blood, Oncology, and Cancer. In addition, he currently serves as a reviewer for a number of journals including Lancet Oncology, Cancer, Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-142-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Ajay Nooka has received honoraria as a consultant from Novartis AG, Onyx, and Spectrum Pharmaceuticals, Inc.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.